KITE Overview
Upcoming Projects (KITE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KITE)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (KITE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (KITE)
-
Kite Expects Investigational New Drug Application in 2018 for KTE-796 in Acute Myeloid Leukemia
Ticker: KITE
Occurred on: Feb 09, 2021 -
Kite Expects Phase 1 ZUMA-6 Data in 2017 Evaluating KTE-C19 in DLBCL and PD-L1 mAb
Ticker: KITE
Occurred on: Dec 03, 2018 -
Kite Expects Investigational New Drug Application in 2018 for KTE-439 in Cervical Cancer and Head and Neck Cancer
Ticker: KITE
Occurred on: Oct 02, 2018 -
Kite Expects First Patient Enrollment in 2017 for ZUMA-8 Trial Evaluating KTE-C19 in Chronic Lymphocytic Leukemia
Ticker: KITE
Occurred on: Aug 09, 2018 -
Kite Expects Data in 2018 From Phase 2 ZUMA-2 Study Evaluating KTE-C19 in Mantle Cell Lymphoma
Ticker: KITE
Occurred on: Jun 01, 2018 -
Kite Expects First Patient Enrollment in 2017 for ZUMA-7 Trial Evaluating KTE-C19 in BLBCL
Ticker: KITE
Occurred on: Jan 15, 2018 -
Kite Pharma (KITE) on Track to Potentially Launch and Commercialize KTE-C19 in Late 2017
Ticker: KITE
Occurred on: Oct 18, 2017 -
Kite Expects Investigational New Drug Application in 2017 for KTE-585 in Multiple Myeloma
Ticker: KITE
Occurred on: Aug 08, 2017 -
Kite Expects First Patient Enrollment in Q1 2017 for ZUMA-5 Study Evaluating KTE-C19 in Indolent Non-Hodgkin Lymphoma
Ticker: KITE
Occurred on: May 08, 2017 -
Kite Expects Phase 1 Data in 2016 for huCD19 Study Evaluating KTE-C19 in B-Cell Malignancies
Ticker: KITE
Occurred on: Mar 14, 2017 -
Kite Primary Analysis of ZUMA-1 Trial Evaluating KTE-C19 in Aggressive Non-Hodgkin Lymphoma
Ticker: KITE
Occurred on: Feb 28, 2017 -
Kite Expects Phase 2 Data in 2017 for Expansion Study Evaluating KTE-C19 in Aggressive Non-Hodgkin Lymphoma
Ticker: KITE
Occurred on: Feb 08, 2017 -
Kite Expects Investigational New Drug Application in 2016 for KTE-718 in Non-Small Cell Lung Cancer and Bladder Cancer
Ticker: KITE
Occurred on: Jan 03, 2017 -
Kite Expects Initial Phase 1 ZUMA-4 Data in 2016 Evaluating KTE-C19 in Pediatric Acute Lymphoblastic Leukemia
Ticker: KITE
Occurred on: Dec 04, 2016 -
Kite Expects Initial Phase 1 ZUMA-3 Data Evaluating KTE-C19 in Adult Acute Lymphoblastic Lymphoma in 2016
Ticker: KITE
Occurred on: Dec 04, 2016 -
Kite Pharma (KITE) expects to file for Biologics License Application (BLA) for KTE-C19 before 2017
Ticker: KITE
Occurred on: Dec 04, 2016 -
Juno Therapeutics (JUNO) Suspends Phase 2 ROCKET Study Assessing JCAR015 in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Tickers: JUNO, KITE, CLLS
Occurred on: Nov 23, 2016 -
Interim Results from Pivotal Phase 2 Portion of ZUMA-1 Clinical Trial of KTE-C19 Expected in September 2016
Ticker: KITE
Occurred on: Sep 26, 2016 -
Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies
Ticker: KITE
Occurred on: Jul 25, 2016 -
Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results
Tickers: INNOVATIVE CELLULAR THERAPEUTICS, NVS, JUNO, KITE
Occurred on: May 06, 2016 -
NIH study results of off-the-shelf CAR-Ts pose threat to designer CAR-T producers Kite Pharma (KITE) and Juno Therapeutics (JUNO)
Tickers: KITE, CLLS, JUNO
Occurred on: Jan 26, 2016 -
Kite Pharma (KITE) Prices Public Offering of 3.625M shares of common stock at $69 per share
Ticker: KITE
Occurred on: Dec 11, 2015 -
Kite Pharma (KITE) to launch Phase 1 studies ZUMA-3 and ZUMA-4 Assessing KTE-C19 in Patients with Acute Lymphoblastic Leukemia
Ticker: KITE
Occurred on: Nov 12, 2015
Strategic Initiatives (KITE)
-
Gilead Sciences (GILD) to Acquire Kite Pharma (KITE) for $11.9 Billion
Tickers: GILD, KITE
Announcement Date: Aug 28, 2017 -
Kite Forms Joint Venture with Shanghai Fosun Pharmaceutical Group (SFOSF) to Develop, Manufacture and Commercialize Axicabtagene Ciloleucel
Tickers: KITE, SFOSF
Announcement Date: Jan 10, 2017 -
Kite Agrees to Development and Commercialization Deal with Daiichi Sankyo (DSNKY) for Lead Product Candidate Axicabtagene Ciloleucel (KTE-C19) in Japan
Tickers: KITE, DSNKY
Announcement Date: Jan 09, 2017 -
Novartis disbands its pioneering cell and gene therapy unit
Tickers: NVS, JUNO, KITE
Announcement Date: Aug 31, 2016 -
BioLife Solutions Executes 10 Year Supply Agreement with Kite Pharma for CryoStor Use in CAR T Cell Therapies
Tickers: BLFS, KITE
Announcement Date: Jul 11, 2016